CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that it was added to the Russell 3000® and Russell 2000® Indexes when Russell Investment Group reconstituted its family of U.S. indexes after stock market close on June 26, 2009.
